A settlement was reached in a class action lawsuit that sought broader coverage of costly hepatitis C drugs for Medicaid patients in Washington state.
The Health Care Authority on Monday reached a settlement agreement in a class action lawsuit that sought broader coverage of costly hepatitis C drugs for Medicaid patients in Washington state.
The settlement has yet to be approved by a judge but lawyers are hopeful it will be soon.
In the past several years, multiple pharmaceutical companies nationwide have developed direct-acting antiviral drugs that cure hepatitis C in more than 90 percent of patients. But the drugs are extremely expensive – for example, Harvoni, introduced in 2014, has a list price of $1,100 a day, or $94,500 for a 12-week course. (After automatic drug rebates and other discounts, Medicaid pays about half that price for each patient.)
But under the state’s previous restrictions, Medicaid patients with hepatitis C could only access the expensive curative drugs if they had advanced liver disease, gauged by a “fibrosis” score, which measures the level of scarring on the liver.
|Read Full Article: Settlement reached on state Medicaid denial of pricy hep C drugs | Local | yakimaherald.com|